Literature DB >> 33673618

Dietary Phosphorus as a Marker of Mineral Metabolism and Progression of Diabetic Kidney Disease.

Agata Winiarska1, Iwona Filipska1, Monika Knysak1, Tomasz Stompór1.   

Abstract

Phosphorus is an essential nutrient that is critically important in the control of cell and tissue function and body homeostasis. Phosphorus excess may result in severe adverse medical consequences. The most apparent is an impact on cardiovascular (CV) disease, mainly through the ability of phosphate to change the phenotype of vascular smooth muscle cells and its contribution to pathologic vascular, valvular and other soft tissue calcification. Chronic kidney disease (CKD) is the most prevalent chronic disease manifesting with the persistent derangement of phosphate homeostasis. Diabetes and resulting diabetic kidney disease (DKD) remain the leading causes of CKD and end-stage kidney disease (ESRD) worldwide. Mineral and bone disorders of CKD (CKD-MBD), profound derangement of mineral metabolism, develop in the course of the disease and adversely impact on bone health and the CV system. In this review we aimed to discuss the data concerning CKD-MBD in patients with diabetes and to analyze the possible link between hyperphosphatemia, certain biomarkers of CKD-MBD and high dietary phosphate intake on prognosis in patients with diabetes and DKD. We also attempted to clarify if hyperphosphatemia and high phosphorus intake may impact the onset and progression of DKD. Careful analysis of the available literature brings us to the conclusion that, as for today, no clear recommendations based on the firm clinical data can be provided in terms of phosphorus intake aiming to prevent the incidence or progression of diabetic kidney disease.

Entities:  

Keywords:  CKD progression; chronic kidney disease; diabetic kidney disease; hyperphosphatemia; phosphaturia; phosphorus intake

Year:  2021        PMID: 33673618      PMCID: PMC7997399          DOI: 10.3390/nu13030789

Source DB:  PubMed          Journal:  Nutrients        ISSN: 2072-6643            Impact factor:   5.717


  97 in total

Review 1.  Role of fetuin-A in atherosclerosis associated with diabetic patients.

Authors:  Monika Singh; Pramod Kumar Sharma; Vipin Kumar Garg; Shambhu Charan Mondal; Avnesh Kumar Singh; Nikhlesh Kumar
Journal:  J Pharm Pharmacol       Date:  2012-07-04       Impact factor: 3.765

2.  Relation between serum phosphate level and cardiovascular event rate in people with coronary disease.

Authors:  Marcello Tonelli; Frank Sacks; Marc Pfeffer; Zhiwei Gao; Gary Curhan
Journal:  Circulation       Date:  2005-10-25       Impact factor: 29.690

3.  Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD.

Authors:  Joanne L Reynolds; Alexis J Joannides; Jeremy N Skepper; Rosamund McNair; Leon J Schurgers; Diane Proudfoot; Willi Jahnen-Dechent; Peter L Weissberg; Catherine M Shanahan
Journal:  J Am Soc Nephrol       Date:  2004-11       Impact factor: 10.121

Review 4.  Serum Phosphorus and Progression of CKD and Mortality: A Meta-analysis of Cohort Studies.

Authors:  Jingjing Da; Xinfang Xie; Myles Wolf; Sinee Disthabanchong; Jinwei Wang; Yan Zha; Jicheng Lv; Luxia Zhang; Haiyan Wang
Journal:  Am J Kidney Dis       Date:  2015-03-21       Impact factor: 8.860

5.  The effects of diabetes mellitus and diabetic nephropathy on bone and mineral metabolism in T2DM patients.

Authors:  Hui Chen; Xiaoxu Li; Ruihong Yue; Xuan Ren; Xiude Zhang; Anming Ni
Journal:  Diabetes Res Clin Pract       Date:  2013-03-21       Impact factor: 5.602

6.  Insulin suppresses the production of fibroblast growth factor 23 (FGF23).

Authors:  Ludmilla Bär; Martina Feger; Abul Fajol; Lars-Oliver Klotz; Shufei Zeng; Florian Lang; Berthold Hocher; Michael Föller
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-14       Impact factor: 11.205

7.  Effect of phosphate omission on the glucose-induced insulin release in vitro in fed and fasted rats.

Authors:  M Castillo; J E Campillo; M Martinez Valdivia; C Osorio
Journal:  Acta Diabetol Lat       Date:  1982 Jul-Sep

8.  Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).

Authors:  Marinella Ruospo; Suetonia C Palmer; Patrizia Natale; Jonathan C Craig; Mariacristina Vecchio; Grahame J Elder; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2018-08-22

9.  Relationship of dietary phosphate intake with risk of end-stage renal disease and mortality in chronic kidney disease stages 3-5: The Modification of Diet in Renal Disease Study.

Authors:  Umut Selamet; Hocine Tighiouart; Mark J Sarnak; Gerald Beck; Andrew S Levey; Geoffrey Block; Joachim H Ix
Journal:  Kidney Int       Date:  2016-01-04       Impact factor: 10.612

Review 10.  Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection.

Authors:  Yi-Chou Hou; Cai-Mei Zheng; Tzung-Hai Yen; Kuo-Cheng Lu
Journal:  Int J Mol Sci       Date:  2020-10-22       Impact factor: 5.923

View more
  2 in total

1.  A long non-coding RNA H19/microRNA-138/TLR3 network is involved in high phosphorus-mediated vascular calcification and chronic kidney disease.

Authors:  Qiang Liu; Huimeng Qi; Li Yao
Journal:  Cell Cycle       Date:  2022-04-18       Impact factor: 5.173

2.  Vitamin D with Calcium Supplementation Managing Glycemic Control with HbA1c and Improve Quality of Life in Patients with Diabetes

Authors:  Sanjana Mehta; Parminder Nain; Bimal K Agrawal; Rajinder Pal Singh
Journal:  Turk J Pharm Sci       Date:  2022-04-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.